CIK 0001098972 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2017 | FY2016 | |
|---|---|---|---|---|
| Revenue (USD) | 114.2 M | 98.0 M | ||
| Net income (USD) | -120.7 M | -42.5 M | ||
| Diluted EPS (USD/shares) | 0 | -15.64 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-02 | 4 | 4 | 2026-10-01 |
| 2026-10-02 | 4 | 4 | 2026-10-01 |
| 2026-09-16 | 4 | 4 | 2026-08-05 |
| 2026-09-15 | 3 | 3 | 2026-08-05 |
| 2026-09-11 | S-3 | S-3 | |
| 2026-09-02 | S-8 | S-8 | |
| 2026-08-18 | 8-K | 8-K items 1.01,2.03,3.02 | 2026-08-12 |
| 2026-08-17 | 424B3 | 424B3 | |
| 2026-08-14 | EFFECT | EFFECT items ,, | |
| 2026-08-13 | 8-K | 8-K items 5.02 | 2026-08-10 |
| 2026-08-12 | 4 | 4 | 2026-08-10 |
| 2026-08-11 | 8-K | 8-K items 5.02 | 2026-08-05 |
| 2026-08-11 | 4 | 4 | 2026-08-05 |
| 2026-08-11 | 4 | 4 | 2026-08-05 |
| 2026-08-07 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-07 | S-8 | S-8 | |
| 2026-08-07 | S-3 | S-3 | |
| 2026-08-07 | 4 | 4 | 2026-08-05 |
| 2026-08-07 | 4 | 4 | 2026-08-05 |
| 2026-08-07 | 4 | 4 | 2026-08-05 |
| 2026-08-07 | 4 | 4 | 2026-08-05 |
| 2026-08-06 | 8-K | 8-K items 2.02 | 2026-08-06 |
| 2026-07-27 | EFFECT | EFFECT items ,, | |
| 2026-07-27 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-20 | SCHEDULE 13G | SCHEDULE 13G |
Forms on file (last 1,000): 4 512, 8-K 162, 10-Q 38, SC 13G/A 38, CORRESP 22, SC 13G 20, CT ORDER 20, UPLOAD 19. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=AGEN (0.002 USD), /gw/filings/filings?ticker=AGEN&form=8-K, /gw/filings/facts?ticker=AGEN&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange